Effect of valsartan on renal function in patients with hypertension and stable renal insufficiency

[1]  Hongjie Zheng,et al.  LONG TERM SAFETY, TOLERABILITY AND EFFICACY OF VALSARTAN : RESULTS FROM ONE AND TWO YEAR TRIALS , 1998 .

[2]  N. Brown,et al.  Recurrent Angiotensin‐Converting Enzyme Inhibitor‐Associated Angioedema , 1998, JAMA.

[3]  A. Bremner,et al.  Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. , 1997, Clinical and experimental hypertension.

[4]  N. Perico,et al.  Efficacy and Tolerability of Valsartan Compared with Lisinopril in Patients with Hypertension and Renal Insufficiency , 1997 .

[5]  K. Goa,et al.  Valsartan , 1997, Drugs.

[6]  J. Levine,et al.  Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril , 1997, Journal of Human Hypertension.

[7]  N. Chaturvedi.  Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria , 1997, The Lancet.

[8]  D. Goldsmith.  Angiotensin receptor antagonists , 1997, The Lancet.

[9]  M. Perazella,et al.  Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance? , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  S. Oparil,et al.  The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. , 1996, Clinical therapeutics.

[11]  R. Fogari,et al.  Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril , 1996, Journal of hypertension.

[12]  R. Fogari,et al.  Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine , 1996, Clinical pharmacology and therapeutics.

[13]  M. Burnier,et al.  Renal effects of angiotensin II receptor blockade in normotensive subjects. , 1996, Kidney international.

[14]  F. Locatelli,et al.  Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency , 1996 .

[15]  C. Johnston,et al.  Angiotensin receptor antagonists: focus on losartan , 1995, The Lancet.

[16]  T. Risler,et al.  Renal hemodynamics in essential hypertensives treated with losartan. , 1995, Clinical nephrology.

[17]  M. de Gasparo,et al.  Pharmacology of angiotensin II receptors in the kidney. , 1994, Kidney international.

[18]  D. Ganten,et al.  Widespread tissue distribution of human chymase. , 1994, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[19]  B. Materson,et al.  Angiotensin-converting enzyme inhibitors in hypertension. A dozen years of experience. , 1994, Archives of internal medicine.

[20]  D. de Zeeuw,et al.  Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? , 1994, Kidney international.

[21]  J. Ménard,et al.  Summary of 1993 World Health Organisation-International Society of Hypertension guidelines for the management of mild hypertension. Subcommittee of WHO/ISH Mild Hypertension Liaison committee. , 1993, BMJ.

[22]  C. Halstenson,et al.  New Therapeutic Agents in the Management of Hypertension: Angiotensin II-Receptor Antagonists and Renin Inhibitors , 1993, The Annals of pharmacotherapy.

[23]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[24]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[25]  P. Timmermans,et al.  Angiotensin II receptors and angiotensin II receptor antagonists. , 1993, Pharmacological reviews.

[26]  E. Thervet,et al.  Angiotensin-converting enzyme (ACE) inhibitors have been reported to induce or worsen anemia in patients on hemodialysis. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  C. Russell,et al.  Quantitation of renal function with technetium-99m MAG3. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  J. Weening,et al.  Membranous glomerulopathy in a patient on captopril. , 2009, Acta medica Scandinavica.

[29]  N Veall,et al.  Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA. , 1969, Clinical science.